Literatur
-
1
Blum H E, Linhart H G.
Gene therapy
for hepatocellular carcinoma.
Viral Hepatitis.
1999;
5
147
-
2
Butterfield L H. et al .
Generation of human T-cell responses to
an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Cancer
Res.
1999;
59
3134
-
3
Geissler M, Mohr L, Weth R, Kohler G, Grimm C F, Krohne T U, Von Weizsäcker F, Blum H E.
Immunotherapy
Directed Against alpha_fetoprotein Results in Autoimmune Liver
Disease During Liver Regeneration in Mice.
Gastroenterology.
2001;
121
931
-
4
Grimm C, Ortmann D, Mohr L, Blum H E, Hauser H, Geissler M.
Mouse α-fetoprotein-specific
DNA-Based immunotherapy of hepatocellular carcinoma leads to tumor
regression in mice.
Gastroenterology.
2000;
119
1104
-
5
Kroger A, Ortmann D, Krohne T M, Mohr L, Blum H E, Hauser H, Geissler M.
Growth suppression of
the hepatocellular carcinoma cell line Hepa1-6 by an activatable
interferon regulatory factor-1 in mice.
Cancer Res.
2001;
61
2609
-
6
Matzinger P.
Tolerance,
danger and the extended family.
Annu Rev Immunol.
1994;
12
991-1045
-
7
Vollmer C M Jr. et al .
Alpha-fetoprotein-specific genetic immunotherapy
for hepatocellular carcinoma.
Cancer Res.
1999;
59
3064
-
8
Zitvogel L, Angevin E, Tursz T.
Dendritic
cell-based immunotherapy of cancer.
Ann Oncol.
2000;
11
199-205
PD Dr. Michael Geissler
Dr. Leonhard Mohr
Prof. Dr. Dr. h.c. Hubert E. Blum
Medizinische Universitätsklinik Freiburg, Abteilung
Innere Medizin II
Hugstetter Straße 55
79106 Freiburg
